Imatinib mesylate (Gleevec) hepatotoxicity

Digestive Diseases and Sciences

Volumn 52, Issue 2, 2007, Pages 598-601

  Mindikoglu, Ayse L ^a   Regev, Arie ^a   Bejarano, Pablo A ^a   Martinez, Enrique J ^a   Jeffers, Lennox J ^a   Schiff, Eugene R ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

CML; GIST; Gleevec; Hepatotoxicity; Imatinib mesylate

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ASCORBIC ACID; ASPARTATE AMINOTRANSFERASE; CELECOXIB; CHONDROITIN SULFATE; GLUCOSAMINE SULFATE; IMATINIB; LACTATE DEHYDROGENASE; MULTIVITAMIN;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIOCHEMISTRY; CASE REPORT; CELL LOSS; CHRONIC MYELOID LEUKEMIA; DISEASE SEVERITY; DRUG WITHDRAWAL; HUMAN; HUMAN TISSUE; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER BIOPSY; LIVER CELL; LIVER TOXICITY; MALE; PRIORITY JOURNAL;

AGED; ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENTS; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; BLOOD CELL COUNT; ERYTHROCYTE INDICES; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LIVER FAILURE; MALE; NECROSIS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTHROMBIN TIME; PYRIMIDINES; TIME FACTORS;

EID: 33846839517     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-006-9117-1     Document Type: Article

References (11)

1. Johnson JR, Bross P, Cohen M, Rothmann, Chen G, Zajicek A, Gobburu J, Rahman A, Staten A, Pazdur R (2003) Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Clin Cancer Res 9:1972-1979
2. Guilhot F (2004) Indications for imatinib mesylate therapy and clinical management. The Oncologist 9:271-281
3. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantajian H, Capdeville R, Ohno-Jones S, Sawyers CL (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037
4. Kikuchi S, Muroi K, Takahashi S, Kawano-Yamamoto C, Takatoku M, Miyazato A, Nagai T, Mori M, Komatsu N, Ozawa K (2004) Severe hepatitis and complete molecular response caused by imatinib mesylate: possible association of its concentration with clinical outcomes. Leukemia Lymphoma 45:2349-2351
5. Novartis (2006) Gleevec® (Imatinib mesylate).www.gleevec.com. Cited 2006
6. Ohyashiki K, Kuriyama Y, Nakajima A, Tauchi T, Ito Y, Miyazawa K, Kimura Y, Serizawa H, Ebihara Y (2004) Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis. Leukemia 16:2160-2161
7. Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, Benson K, Leighton J, Kim SK, Wood R, Rothmann M, Chen GUKM, Staten AM, Pazdur R (2002) Approval Summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 8:935-942
8. Lin NU, Sarantopoulos S, Stone JR, Galinsky I, Stone RM, Deangelo DJ, Soiffer RJ (2003) Fatal hepatic necrosis following imatinib mesylate therapy. Blood 102:3455-3456
9. James C, Trouette H, Marit G, Cony-Makhoul P, Mahon F-X (2003) Histological features of acute hepatitis after imatinib mesylate treatment. Leukemia 17:978-979
10. Ayoub WS, Geller SA, Tran T, Martin P, Vierling JM, Poordad FF (2005) Imatinib (Gleevec®)-induced hepatotoxicity. J Cin Gastroenterol 39:75-77
11. Consult MD (2005) Celecoxib. www. mdconsult.com. Cited 2005